Coherus BioSciences Inc (CHRS):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Coherus BioSciences Inc (CHRS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8247)・商品コード:DATA904C8247
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:57
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Coherus BioSciences Inc (Coherus) is a biosimilar platform company that develops and commercializes biosimilar drugs. The company’s pipeline product candidates include CHS-1701, an pegfilgrastim used to treat febrile neutropenia; CHS-0214, is an etanercept biosimilar candidate which is used for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriasis, psoriasis arthritis and rheumatoid arthritis; and CHS-1420, is a adalimumab biosimilar candidate,which is being developed to treat crohn’s disease, ulcerative colitis, and psoriasis arthritis, among others. Coherus capabilities includes process science, analytical characterization, protein production and clinical-regulatory development. The company develops drugs in collaboration with other organizations. Coherus is headquartered in Redwood City, California, the US.

Coherus BioSciences Inc (CHRS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Coherus BioSciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Coherus BioSciences Raises USD55 Million in Series C Venture Financing 12
Coherus BioSciences Raises US$28 Million In Venture Financing 14
Coherus BioSciences Raises US$46.3 Million In Venture Financing 15
Partnerships 16
Baxter Amends Co-Development Agreement with Coherus Biosciences 16
Licensing Agreements 17
Coherus BioSciences Enters into Licensing Agreement with Genentech 17
Orox Pharma Enters into Licensing Agreement with Coherus BioSciences 18
Equity Offering 19
Coherus Biosciences Prices Public Offering of Shares for USD75 Million 19
Coherus BioSciences Plans to Raise up to USD8.4 Million in Public Offering of Shares 21
Coherus Biosciences Raises USD6.8 Million in Private Placement of Shares 22
Coherus BioSciences Files Registration Statement to Raise Funds through Public Offering of Shares 23
Coherus BioSciences to Raise USD75 Million in Private Placement of Shares 24
Coherus Biosciences Prices Public Offering of Shares for USD125 Million 26
Coherus Biosciences Raises USD60.8 Million in Public Offering of Shares 28
Coherus BioSciences Prices Public Offering of Shares for USD63 Million 30
Coherus BioSciences Raises USD10 Million in Private Placement of Shares 31
Coherus BioSciences Prices Public Offering of Shares for USD120 Million 32
Coherus BioSciences Raises USD92 Million in IPO of Shares 34
Coherus BioSciences Raises USD2.5 Million in Private Placement of Shares 36
Debt Offering 37
Coherus BioSciences Raises USD100 Million in Private Placement of 8.2% Notes Due 2022 37
Acquisition 39
Coherus BioSciences Acquires InteKrin Therapeutics for USD5 Million 39
Coherus BioSciences Inc – Key Competitors 40
Coherus BioSciences Inc – Key Employees 41
Coherus BioSciences Inc – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
Aug 08, 2018: Coherus BioSciences reports corporate highlights and second quarter 2018 financial results 43
May 10, 2018: Coherus BioSciences Reports Corporate Highlights and First Quarter 2018 Financial Results 44
Mar 08, 2018: Coherus BioSciences Announces Fourth Quarter and Full Year 2017 Financial Results 45
Nov 06, 2017: Coherus BioSciences Reports Third Quarter 2017 Operating and Financial Results 46
Aug 07, 2017: Coherus BioSciences Reports Second Quarter 2017 Corporate Highlights and Financial Results 48
May 08, 2017: Coherus BioSciences Reports First Quarter 2017 Corporate Highlights and Financial Results 50
Mar 13, 2017: Coherus BioSciences Reports Fourth Quarter and Full Year 2016 Corporate Highlights and Financial Results 52
Corporate Communications 54
May 10, 2018: Coherus BioSciences Appoints Samuel Nussbaum to Board of Directors 54
Mar 27, 2017: Coherus BioSciences Appoints Erik Wiberg as Executive Vice President of Corporate Development 55
Legal and Regulatory 56
Mar 06, 2017: Coherus Addresses Trade Secret Action Filed by Amgen 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Coherus BioSciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Coherus BioSciences Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Coherus BioSciences Raises USD55 Million in Series C Venture Financing 12
Coherus BioSciences Raises US$28 Million In Venture Financing 14
Coherus BioSciences Raises US$46.3 Million In Venture Financing 15
Baxter Amends Co-Development Agreement with Coherus Biosciences 16
Coherus BioSciences Enters into Licensing Agreement with Genentech 17
Orox Pharma Enters into Licensing Agreement with Coherus BioSciences 18
Coherus Biosciences Prices Public Offering of Shares for USD75 Million 19
Coherus BioSciences Plans to Raise up to USD8.4 Million in Public Offering of Shares 21
Coherus Biosciences Raises USD6.8 Million in Private Placement of Shares 22
Coherus BioSciences Files Registration Statement to Raise Funds through Public Offering of Shares 23
Coherus BioSciences to Raise USD75 Million in Private Placement of Shares 24
Coherus Biosciences Prices Public Offering of Shares for USD125 Million 26
Coherus Biosciences Raises USD60.8 Million in Public Offering of Shares 28
Coherus BioSciences Prices Public Offering of Shares for USD63 Million 30
Coherus BioSciences Raises USD10 Million in Private Placement of Shares 31
Coherus BioSciences Prices Public Offering of Shares for USD120 Million 32
Coherus BioSciences Raises USD92 Million in IPO of Shares 34
Coherus BioSciences Raises USD2.5 Million in Private Placement of Shares 36
Coherus BioSciences Raises USD100 Million in Private Placement of 8.2% Notes Due 2022 37
Coherus BioSciences Acquires InteKrin Therapeutics for USD5 Million 39
Coherus BioSciences Inc, Key Competitors 40
Coherus BioSciences Inc, Key Employees 41
Coherus BioSciences Inc, Subsidiaries 42

List of Figures
Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[Coherus BioSciences Inc (CHRS):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8247)販売に関する免責事項を必ずご確認ください。
★調査レポート[Coherus BioSciences Inc (CHRS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆